Lydia H. Kennard
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vulcan Materials Prepares for Q3 2026 Earnings; JP Morgan Lowers Target to $300. Vulcan Materials announced its third‑quarter 2026 earnings call will take place on Thursday. The company is preparing to report its quarterly results, which investors will watch closely. JP Morgan has kept a neutral rating and cut its price target to $300, below the current average target of $308.30. The move reflects the firm’s assessment of the upcoming earnings release.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Prologis Reports Earnings Beat, Raises 2026 Development Outlook. Prologis posted earnings that exceeded analysts' expectations for the quarter. The company also lifted its 2026 development outlook to $5.75 billion, indicating confidence in future projects. Management noted rent recovery but highlighted ongoing rate‑risk concerns. The stock is trading near a long‑standing support level around $140 and its RSI is below 40, suggesting modest momentum.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
AECOM's backlog growth fuels debate on valuation. Recent reports highlight AECOM's record backlog and suggest the stock may be undervalued by up to 35%. Analysts note that legacy contract charges are easing and core growth could support 5‑8% organic expansion. A comparison with Tutor Perini shows AECOM’s design franchise remains strong, but the company faces headwinds that could affect future performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Healthpeak Sets Q3 2026 Earnings Date and Declares Q4 Dividend. Healthpeak Properties announced the dates for its third‑quarter 2026 earnings release, conference call, and webcast. The company also declared a monthly common‑stock cash dividend for the fourth quarter of 2026. These updates give investors a schedule for upcoming earnings and confirm the firm’s continued dividend payments, which can influence trading activity.
Transaction History
| FCX | ▼ Sell | Open Market | 3,798 | $300K | 8/27/2026 | View on chart |
| VMC | ▲ Buy | Option Exercise | 655 | — | 6/12/2026 | View on chart |
| FCX | ▲ Buy | Grant | 2,800 | $0 | 6/1/2026 | View on chart |
| PLD | ▲ Buy | Option Exercise | 1,984 | $0 | 4/28/2026 | View on chart |
| VMC | ▲ Buy | Option Exercise | 630 | $0 | 6/13/2025 | View on chart |
| FCX | ▲ Buy | Grant | 4,900 | $0 | 6/1/2025 | View on chart |
| PLD | ▲ Buy | Option Exercise | 1,617 | $0 | 5/4/2025 | View on chart |
| VMC | ▲ Buy | Option Exercise | 827 | $0 | 6/17/2024 | View on chart |
| FCX | ▲ Buy | Grant | 3,500 | $0 | 6/1/2024 | View on chart |
| PLD | ▲ Buy | Option Exercise | 1,762 | $0 | 4/29/2024 | View on chart |
| ACM | ▲ Buy | Grant | 1,789 | $0 | 3/19/2024 | View on chart |
| PLD | ▼ Sell | Gift | 8,605 | $0 | 12/27/2023 | View on chart |
| FCX | ▲ Buy | Grant | 5,000 | $0 | 6/1/2023 | View on chart |
| PLD | ▲ Buy | Option Exercise | 2,261 | $0 | 4/29/2023 | View on chart |
| ACM | ▲ Buy | Grant | 1,987 | $0 | 3/31/2023 | View on chart |
| ACM | ▲ Buy | Option Exercise | 2,297 | $0 | 3/1/2023 | View on chart |
| FCX | ▲ Buy | Grant | 4,500 | $0 | 6/1/2022 | View on chart |
| PLD | ▲ Buy | Option Exercise | 2,621 | $0 | 5/1/2022 | View on chart |
| DOC | ▲ Buy | Grant | 5,258 | $0 | 4/28/2022 | View on chart |
| ACM | ▲ Buy | Option Exercise | 2,673 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FCX Grasberg on schedule amid cash flow valuation questions
Recent news highlights that Freeport-McMoRan's Grasberg operation is back on schedule, supporting its production outlook. However, market commentary questions whether the stock is priced for perfection on cash flow, with copper prices acting as a key test. The company's valuation of 33.9 times trailing earnings reflects high market expectations for cash flow delivery.
FCX Grasberg on schedule amid cash flow valuation questions. Recent news highlights that Freeport-McMoRan's Grasberg operation is back on schedule, supporting its production outlook. However, market commentary questions whether the stock is priced for perfection on cash flow, with copper prices acting as a key test. The company's valuation of 33.9 times trailing earnings reflects high market expectations for cash flow delivery.